MUVON's CEO Deana Mohr featured in Top 30 In Vivo's Rising Leaders 2022
MUVON Therapeutics, a spin-off from the University of Zurich developing a platform technology for the regeneration of skeletal muscle tissue, is proud to announce that its CEO and co-founder Deana Mohr, PhD, has been listed on the Top 30 In Vivo’s '2022 Rising Leaders'.
The list features 30 investors, entrepreneurs and innovators with biopharma and medtech businesses from all over the world who drive health initiatives forward with their talent, creativity and strong leadership qualities.
“It is my greatest honor to be nominated as one of In Vivo’s 30 Rising Leaders 2022, just before starting our Phase II clinical trial with our lead candidate. The excitement is huge and a great motivator to keep on working hard on the fast transition of our pipeline indications to clinics”, says Deana Mohr, CEO from MUVON. She congratulates everyone cordially who is featured in this list of extraordinary achievers.
Check out the 30 listed rising leaders across the biopharma, medtech and health technology sectors here: In Vivo’s 2022 Rising Leaders: Putting A Spotlight On Talent :: In Vivo (informa.com)